

Angptl4 Polyclonal Antibody
Catalog # AP73357**Specification****Angptl4 Polyclonal Antibody - Product Information**

Application	IHC
Primary Accession	Q9BY76
Reactivity	Human, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal

Angptl4 Polyclonal Antibody - Additional Information**Gene ID** 51129**Other Names**

ANGPTL4; ARP4; HFARP; PGAR; PP1158; PSEC0166; Angiopoietin-related protein 4; Angiopoietin-like protein 4; Hepatic fibrinogen/angiopoietin-related protein; HFARP

Dilution

IHC~~IHC-p: 100-300. Western Blot: 1/500 - 1/2000. ELISA: 1/20000. Not yet tested in other applications.

Format

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% (W/V) sodium azide.

Storage Conditions

-20°C

Angptl4 Polyclonal Antibody - Protein Information**Name** ANGPTL4**Synonyms** ARP4, HFARP, PGAR {ECO:0000303|PubMed:10**Function**

Mediates inactivation of the lipoprotein lipase LPL, and thereby plays a role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism (PubMed: [19270337](http://www.uniprot.org/citations/19270337), PubMed: [21398697](http://www.uniprot.org/citations/21398697), PubMed: [27929370](http://www.uniprot.org/citations/27929370), PubMed: [29899144](http://www.uniprot.org/citations/29899144)). May also play a role in regulating glucose homeostasis and insulin sensitivity (Probable). Inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage (PubMed: [14583458](http://www.uniprot.org/citations/14583458), PubMed: [17068295](http://www.uniprot.org/citations/17068295)). Upon heterologous expression, inhibits the adhesion of endothelial cell to the extracellular matrix (ECM), and inhibits the reorganization of the actin cytoskeleton, formation of actin stress fibers

and focal adhesions in endothelial cells that have adhered to ANGPTL4-containing ECM (in vitro) (PubMed:17068295). Depending on context, may modulate tumor-related angiogenesis (By similarity).

Cellular Location

Secreted. Secreted, extracellular space, extracellular matrix. Note=The unprocessed form interacts with the extracellular matrix (PubMed:17068295, PubMed:21398697). This may constitute a dynamic reservoir, a regulatory mechanism of the bioavailability of ANGPTL4 (Probable).

Tissue Location


Detected in blood plasma (at protein level) (PubMed:29899519). Detected in liver (PubMed:10698685). Detected in white fat tissue and placenta (PubMed:10866690). Expressed at high levels in the placenta, heart, liver, muscle, pancreas and lung but expressed poorly in the brain and kidney.




Angptl4 Polyclonal Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Angptl4 Polyclonal Antibody - Images





Angptl4 Polyclonal Antibody - Background

Protein with hypoxia-induced expression in endothelial cells. May act as a regulator of angiogenesis and modulate tumorigenesis. Inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage. May exert a protective function on endothelial cells through an endocrine action. It is directly involved in regulating glucose homeostasis, lipid metabolism, and insulin sensitivity. In response to hypoxia, the unprocessed form of the protein accumulates in the subendothelial extracellular matrix (ECM). The matrix-associated and immobilized unprocessed form limits the formation of actin stress fibers and focal contacts in the adhering endothelial cells and inhibits their adhesion. It also decreases motility of endothelial cells and inhibits the sprouting and tube formation (By similarity).